METTL14 and ankylosing spondylitis: METTL14-mediated m6A modification of the ELMO1 3’UTR has been shown to enhance directional migration and osteogenic differentiation of MSCs, thereby improving the therapeutic efficacy in ankylosing spondylitis[36].